[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100582326":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":24,"locations":30,"responsibleParty":42,"collaborators":10,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":10,"eligibilityCriteria":52,"healthyVolunteers":48,"sex":53,"minAge":10,"maxAge":10,"enrollmentInfo":54,"targetDuration":10,"studyType":57,"phases":10,"briefSummary":58,"conditions":59,"keywords":10,"overallStatus":62,"whyStopped":10,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},{"fullName":5,"class":6},"Assiut University","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"endometrial carcinoma",null,[12,13],"Other: Observation","Behavioral: IHC",[15,19],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"Observation","observation of METTL-14 prognosis",[9],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"BEHAVIORAL","IHC","IHC of METTL-14",[9],[25],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},"Monica Ashraf Alfy, Demonstrator","CONTACT","+2001550303582","mony.ashraf@aun.edu.eg",[31],{"facility":32,"status":10,"city":33,"state":10,"zip":10,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":10},"AssuitU","Asyut","Egypt","EG",{"type":37,"coordinates":38},"Point",[39,40],31.18368,27.18096,{"lat":40,"lon":39},{"type":43,"investigatorFullName":44,"investigatorTitle":45,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Monica Ashraf Alfy","Principal investigator","100582326","prognosis-of-mettl-14-in-endometrial-carcinoma-100582326",false,"NCT06861855","Prognosis of METTL-14 in Endometrial Carcinoma","Prognostic Impact of Immunohistochemical Expression of METTL-14 in Endometrial Carcinoma","Inclusion Criteria:\n\n* Cases of type1endometrial carcinoma with:\n\n  1. Hystrectomy operation\n  2. Available full clinical data about patient (age, complaint, findings in clinical examination).\n  3. Full data about previous biopsy and radiology.\n  4. Full data about patient survival, disease progression and history of chemotherapy for three years.\n\nExclusion Criteria:\n\n* 1\\. Any case of type 1 endometrial carcinoma with missing clinical, radiologic or follow up data.\n\n  2\\. Cases with no available H\\&E stained slides or formalin fixed paraffin embedded block.\n\n  3.D\\&C.","FEMALE",{"count":55,"type":56},50,"ESTIMATED","OBSERVATIONAL","1. To evaluate immunohistochemical expression of METTL14 in type1 endometrial carcinoma.\n2. To evaluate the correlation between METTL14 expression and clinicopathological parameters of patients with type 1endometrial carcinoma such as tumor grade, lymhovascular invasion, age of pateints, tumor stage, presence of myometrial invasion and presence of cervical stroma affection.\n3. To assess correlation of METTL-14 expression with disease free survival and overall survival.",[60,61],"Endometrial Cancer","Endometrial Adenocarcinoma","NOT_YET_RECRUITING","2025-09-29",{"date":65,"type":66},"2025-09-30","ACTUAL",{"date":68,"type":56},"2025-09-27",{"date":70,"type":56},"2026-10",{"name":5,"class":6},1]